Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma

Journal of Immunotherapy

Volumn 31, Issue 6, 2008, Pages 591-598

  Redman, Bruce G ^a,f   Alfred E Chang, ^b   Joel Whitfield, ^b   Peg Esper, ^a   Guihua Jiang, ^b   Thomas Braun, ^c   Blake Roessler, ^d   James J Mule ^e  

^a Division of Hematology/Oncology   (Canada)

^b Division of Surgical Oncology   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Dendritic cell; Immunity; Melanoma; Vaccine

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; MELANOMA VACCINE; CANCER VACCINE;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SIZE; CELL LYSATE; CELL PROLIFERATION; CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; LEUKAPHERESIS; LOW DRUG DOSE; LYMPH NODE CELL; MALAISE; MALE; MELANOMA; MELANOMA CELL; METASTASIS; MONOTHERAPY; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR CELL; UNSPECIFIED SIDE EFFECT; BIOSYNTHESIS; IMMUNOLOGY; MIDDLE AGED; VACCINATION;

ADULT; AGED; CANCER VACCINES; DENDRITIC CELLS; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; INTERFERON TYPE II; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; VACCINATION;

EID: 48549095277     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31817fd90b     Document Type: Article

References (15)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
2. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994;180:83-93.
3. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide or tumor lysate pulsed dendritic cells. Nat Med. 1998;4:328-332.
4. Chang AE, Redman BG, Whitfield JR, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res. 2002;8:1021-1031.
5. Shimizu K, Fields RC, Giedlin M, et al. Systemic administration of interleukin-2 enhances the therapeutic efficacy of dendritic cellbased tumor vaccines. Proc Natl Acad Sci U S A. 1999;96: 2268-2273.
6. Chang AE, Aruga A, Cameron MJ, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated anti- CD3 and interleukin-2. J Clin Oncol. 1997;15:796-807.
7. Palucka AK, Ueno H, Fay J, et al. Role of dendritic cells in cancer immunotherapy. PPO Focus Cancer Immunol. 2007;1:1.
8. den Brok MH, Nierkens S, Figdor CG, et al. Dendritic cells: Tools and targets for antitumor vaccination. Expert Rev Vaccines. 2005; 4:699-710.
9. Chianese-Bullock KA, Woodson EMH, Tao H, et al. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunother. 2005;28:412-419.
10. Escobar A, Lopez M, Ramirez M, et al. Dendritic cell immunization alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol. 2005; 105:555-568.
11. Wiebke EA, Rosenberg SA, Lotze MT. Acute immunological effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigen. J Clin Oncol. 1998;6:1440-1449.
12. Zou W. Immunosuppressive networks in the tumor microenvironment and their therapeutic relevance. Nat Rev Cancer. 2005;5:263-274.
13. Sutmuller RPM, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternate pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001;194:823-832.
14. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65:1089-1096.
15. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115:3623-3633.